Featured Research

from universities, journals, and other organizations

New Rheumatoid Arthritis Treatment Effective, Study Suggests

Date:
June 16, 2007
Source:
European League Against Rheumatism
Summary:
Nearly half -- 43.9 percent -- of rheumatoid arthritis patients receiving tocilizumab 8mg/kg, in addition to ongoing methotrexate therapy experienced a 50 percent improvement in symptoms at 24 weeks and more than one fifth achieved a 70 percent symptom improvement, according to new research.

Nearly half (43.9%) of rheumatoid arthritis (RA) patients receiving tocilizumab 8mg/kg, in addition to ongoing methotrexate therapy experienced a 50% (ACR50) improvement in symptoms at 24 weeks and more than one fifth achieved a 70% symptom improvement, according to results of a European study presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain. This study is the first phase III trial of tocilizumab.

Lead researcher Dr Josef Smolen of the Medical University of Vienna for Internal Medicine commented, "These data show the potential of tocilizumab as a novel and attractive approach to treating RA. The symptom improvements observed across both 4mg/kg and 8mg/kg doses show that tocilizumab offers significant promise to patients with moderate and severe RA."

Significant improvement in symptoms was observed in all patients receiving tocilizumab and methotrexate compared to placebo and methotrexate. At 24 weeks, an ACR70 (70% symptom improvement) was observed in 22%, an ACR50 (50% symptom improvement) in 43.9% and an ACR20 (20% symptom improvement) in 58.5% of patients receiving 8mg/kg tocilizumab plus methotrexate compared to placebo (2.0% p=<0.0001; 10.8% p=<0.0001 and 26.5% p=<0.0001 respectively). An ACR20 was equally noted in 47.9% of patients receiving 4mg/kg tocilizumab plus methotrexate compared to placebo (26.5% p=<0.0001).

A significantly higher proportion of patients treated with tocilizumab and methotrexate achieved a good/moderate EULAR response, observed in 79.5% of patients receiving tocilizumab 8mg/kg and 61.9% patients receiving 4mg/kg tocilizumab, versus 34.8% on placebo.

A reduction in Disease Activity Score (DAS28) was also observed from two weeks onwards in both tocilizumab groups, with a significant change from baseline to week 24 in patients treated with tocilizumab 8mg/kg (-3.43) and 4mg/kg (-2.68) compared to placebo (-1.55, p=0.0001).

The study involved 623 patients with sustained moderate to severe RA despite long standing treatment with methotrexate. Patients received 4mg/kg, 8mg/kg tocilizumab or placebo intravenously every four weeks for a period of 24 weeks. Patients were permitted concurrent treatment with methotrexate at their pre-study dose (10-25mg weekly). Treatment with all other disease modifying anti-rheumatic drugs (DMARDs) was discontinued at the beginning of the trial.

Tocilizumab is a novel humanised anti human interleukin 6 (IIL-6) receptor monoclonal antibody. IL-6 is a cytokine involved in the pathogenesis of RA and by targeted blockage of this receptor, tocilizumab slows down the progression of rheumatoid arthritis.

Adverse Events (AEs) were recorded throughout the duration of the trial with a similar AE profile reported in all three groups (8mg/kg, 4mg/kg and placebo). The AE profile of tocilizumab is consistent with data presented in previous studies with the treatment being generally well tolerated.


Story Source:

The above story is based on materials provided by European League Against Rheumatism. Note: Materials may be edited for content and length.


Cite This Page:

European League Against Rheumatism. "New Rheumatoid Arthritis Treatment Effective, Study Suggests." ScienceDaily. ScienceDaily, 16 June 2007. <www.sciencedaily.com/releases/2007/06/070615094904.htm>.
European League Against Rheumatism. (2007, June 16). New Rheumatoid Arthritis Treatment Effective, Study Suggests. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2007/06/070615094904.htm
European League Against Rheumatism. "New Rheumatoid Arthritis Treatment Effective, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2007/06/070615094904.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Idaho Boy Helps Brother With Disabilities Complete Triathlon

Idaho Boy Helps Brother With Disabilities Complete Triathlon

Newsy (July 23, 2014) An 8-year-old boy helped his younger brother, who has a rare genetic condition that's confined him to a wheelchair, finish a triathlon. Video provided by Newsy
Powered by NewsLook.com
Stone Fruit Listeria Scare Causes Sweeping Recall

Stone Fruit Listeria Scare Causes Sweeping Recall

Newsy (July 22, 2014) The Wawona Packing Company has issued a voluntary recall on the stone fruit it distributes due to a possible Listeria outbreak. Video provided by Newsy
Powered by NewsLook.com
Huge Schizophrenia Study Finds Dozens Of New Genetic Causes

Huge Schizophrenia Study Finds Dozens Of New Genetic Causes

Newsy (July 22, 2014) The 83 new genetic markers could open dozens of new avenues for schizophrenia treatment research. Video provided by Newsy
Powered by NewsLook.com
CDC Head Concerned About a Post-Antibiotic Era

CDC Head Concerned About a Post-Antibiotic Era

AP (July 22, 2014) Sounding alarms about the growing threat of antibiotic resistance, CDC Director Tom Frieden warned Tuesday if the global community does not confront the problem soon, the world will be living in a devastating post-antibiotic era. (July 22) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins